PT  - JOURNAL ARTICLE
AU  - Martin, Christian
AU  - Mahan, Kathleen S.
AU  - Wiggen, Talia D.
AU  - Gilbertsen, Adam J.
AU  - Hertz, Marshall I.
AU  - Hunter, Ryan C.
AU  - Quinn, Robert A.
TI  - Bronchoalveolar lavage metabolome dynamics reflect underlying disease and chronic lung allograft dysfunction
AID  - 10.1101/2022.11.16.22281980
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.16.22281980
4099  - http://medrxiv.org/content/early/2022/11/18/2022.11.16.22281980.short
4100  - http://medrxiv.org/content/early/2022/11/18/2022.11.16.22281980.full
AB  - Background Progression of chronic lung disease often leads to the requirement for a lung transplant (LTX). Despite improvements in short-term survival after LTX, chronic lung allograft dysfunction (CLAD) remains a critical challenge for long-term survival. This study investigates the relationship between the metabolome of bronchoalveolar lavage fluid (BALF) from subjects post-LTX with underlying lung disease and CLAD severity.Methods Untargeted LC-MS/MS metabolomics was performed on 960 BALF samples collected over 10 years from LTX recipients with alpha-1-antitrypsin disease (AATD, n=22), cystic fibrosis (CF, n=46), chronic obstructive pulmonary disease (COPD, n = 79) or pulmonary fibrosis (PF, n=47). Datasets were analyzed using machine learning and multivariate statistics for associations with underlying disease and final CLAD severity.Results BALF metabolomes varied by underlying disease state, with AATD LT recipients being particularly distinctive (PERMANOVA, p=0.001). We also found a significant association with the final CLAD severity score (PERMANOVA, p=0.001), especially those with underlying CF. Association with CLAD severity was driven by changes in phosphoethanolamine (PE) and phosphocholine lipids that increased and decreased, respectively, and metabolites from the bacterial pathogen Pseudomonas aeruginosa. P. aeruginosa siderophores, quorum-sensing quinolones, and phenazines were detected in BALF, and 4-hydroxy-2-heptylquinoline (HHQ) was predictive of the final CLAD stage in samples from CF patients (R=0.34; p≤0.01). Relationships between CLAD stage and P. aeruginosa metabolites were especially strong in those with CF, where 61% of subjects had at least one of these metabolites in their first BALF sample after transplant.Conclusions BALF metabolomes after LTX are distinctive based on the underlying disease and reflect final CLAD stage. In those with more severe outcomes, there is a lipid transition from PC to predominantly PE phospholipids. The association of P. aeruginosa metabolites with CLAD stages in LTX recipients with CF indicates this bacterium and its metabolites may be drivers of allograft dysfunction.Key messages Despite the high prevalence of CLAD among LTX recipients, its pathology is not well understood, and no single molecular indicator is known to predict disease onset. Our machine learning metabolomic-based approach allowed us to identify patterns associated with a shift in the lipid metabolism and bacterial metabolites predicting CLAD onset in CF. This study provides a better understanding about the progression of allograft dysfunction through the molecular transitions within the transplanted lung from the host and bacterial pathogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the CF Foundation grant HUNTER18ABO and the National Institute of Allergy and Infectious Diseases (R01AI145925) provided funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This protocol was approved by the University of Minnesota IRB (STUDY00004547).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.